The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The optimal risk-benefit profile for men with LUTS secondary to BPH was achieved with the tadalafil 5 mg dose (Roehrborn et al 2008).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Roehrborn et al 2008
In the citing paper
“The IPSS mean change from baseline to endpoint after 12 weeks was significantly improved, –3.9 for tadalafil 2.5 mg (p <0.015), −4.9 for tadalafil 5 mg (p < 0.001), −5.2 for tadalafil 10 mg (p < 0.001), and −5.2 for tadalafil 20 mg (p < 0.001), compared with −2.3 for placebo.”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Roehrborn et al 2008
In the citing paper
“To further examine the efficacy and dose response of tadalafil in men with LUTS secondary to BPH, Roehrborn and colleagues performed a similar multicentered, randomized, double-blind, placebo controlled study with a larger sample size and different tadalafil doses (Roehrborn et al 2008).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Roehrborn et al 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tadalafil pharmacokinetics in healthy subjects
Forgue, S. T., Patterson, B. E., Bedding, A. W., Payne, C. D., Phillips, D. L., Wrishko, R. E., & Mitchell, M. I. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02553.x · Cited by 284
Research works printed but not linked: 23
- Wei, 2005, Urologic Diseases in America Project: benign prostatic hyperplasia, J Urol, 173, 1256, 10.1097/01.ju.0000155709.37840.fe · DOI
- Jacobsen, 1997, Natural history of prostatism: risk factors for acute urinary retention, J Urol, 158, 481, 10.1016/S0022-5347(01)64508-7 · DOI
- Sagnier, 1995, Impact of symptoms of prostatism on level of bother and quality of life of men in the French community, J Urol, 153, 669, 10.1016/S0022-5347(01)67681-X · DOI
- Norman, 1994, ‘Prostate-related symptoms’ in Canadian men 50 years of age or older: prevalence and relationships among symptoms, Br J Urol, 74, 542, 10.1111/j.1464-410X.1994.tb09181.x · DOI
- McConnell, 2003, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med, 349, 2387, 10.1056/NEJMoa030656 · DOI
- McVary, 2004, The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence, Curr Urol Rep, 5, 251, 10.1007/s11934-004-0047-1 · DOI
- Uckert, 2001, Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate, J Urol, 166, 2484, 10.1016/S0022-5347(05)65621-2 · DOI
- Filippi, 2007, Characterization and functional role of androgen-dependent PDE5 activity in the bladder, Endocrinology, 148, 1019, 10.1210/en.2006-1079 · DOI
- Gacci, 2007, Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study, J Urol, 178, 2040, 10.1016/j.juro.2007.07.048 · DOI
- Azadzoi, 2003, Chronic ischemia increases prostatic smooth muscle contraction in the rabbit, J Urol, 170, 659, 10.1097/01.ju.0000064923.29954.7e · DOI
- Berger, 2005, Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction, BJU Int, 96, 1073, 10.1111/j.1464-410X.2005.05777.x · DOI
- Pinggera, 2008, Alpha-blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms, BJU Int, 101, 319, 10.1111/j.1464-410X.2007.07339.x · DOI
- Andersson, 2007, Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS, Neurourol Urodyn, 26, 928, 10.1002/nau.20485 · DOI
- Ehren, 1994, Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses, Urology, 44, 683, 10.1016/S0090-4295(94)80206-8 · DOI
- Yoshimura, 2001, Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder, J Neurophysiol, 86, 304, 10.1152/jn.2001.86.1.304 · DOI
- Persson, 1992, Nitric oxide and relaxation of pig lower urinary tract, Br J Pharmacol, 106, 416, 10.1111/j.1476-5381.1992.tb14349.x · DOI
- McVary, 2007, Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia, J Urol, 177, 1401, 10.1016/j.juro.2006.11.037 · DOI · Paper page
- Barry, 1995, Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?, J Urol, 154, 1770, 10.1016/S0022-5347(01)66780-6 · DOI
- Dunn, 2002, Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms, Drugs Aging, 19, 135, 10.2165/00002512-200219020-00004 · DOI
- McVary, 2007, Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial, J Urol, 177, 1071, 10.1016/j.juro.2006.10.055 · DOI
- Stief, 2008, A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia, Eur Urol, 53, 1236, 10.1016/j.eururo.2008.01.075 · DOI
- Porst, 2006, Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial, Eur Urol, 50, 351, 10.1016/j.eururo.2006.02.052 · DOI · Paper page
- Rajfer, 2007, Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US, Int J Impot Res, 19, 95, 10.1038/sj.ijir.3901496 · DOI
Cited by
Tadalafil in the treatment of erectile dysfunction
Coward, R., & Carson, C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3336 · Cited by 138
Metadata
- Authors
- Roehrborn, C. G., McVary, K. T., Elion-Mboussa, A., & Viktrup, L.
- Affiliations
- Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
- Department of Urology, Northwestern University, Chicago, Illinois
- Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana
- Venue
- Journal of Urology
- Published
- 2008-10
- Volume
- 180
- Issue
- 4
- Pages
- 1228-1234
- ISSN
- 0022-5347
- 1527-3792
- Cited by
- 223
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study. https://app.cochat.ai/papers/10.1016/j.juro.2008.06.079
- The paper
- Roehrborn, C. G., McVary, K. T., Elion-Mboussa, A., & Viktrup, L. (2008). Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study. Journal of Urology. https://doi.org/10.1016/j.juro.2008.06.079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
